On May 28, 2019, Khiron Life Sciences Corp. (TSXV:KHRN) (OTCQB:KHRNF) closed its previously announced bought deal short form prospectus offering of common shares, including the exercise in full of the over-allotment option, for aggregate gross proceeds of $28,751,035. The offering was completed by a syndicate of underwriters co-led by Canaccord Genuity Corp. and BMO Capital Markets, and including AltaCorp Capital Inc. and Scotia Capital Inc.
Khiron is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. In May 2018 , Khiron listed on the TSXV, becoming the first Colombian based medical cannabis company to trade on any exchange globally.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.